Pharmacological inhibition of SMYD2 protects against cisplatin-induced renal fibrosis and inflammation

• Main Authors: Min Chen (Author), Siyang Zuo (Author), Siyu Chen (Author), Xia Li (Author), Tian Zhang (Author), Dan Yang (Author), Xue Zou (Author), Yuan Yang (Author), Hehua Long (Author), Rui Peng (Author), Huixiong Yuan (Author), Bing Guo (Author), Lirong Liu (Author)
• Format: Book
• Published: Elsevier, 2023-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

SET and MYND domain protein 2 (SMYD2) can methylate histone H3 at lysine36 (H3K36) and some non-histone substrates to play a role in tumorigenesis. However, It is unclear how SMYD2 contributes to chronic kidney disease (CKD). Here, AZ505 or LLY507, which could inhibit SMYD2, were used in cisplatin-i...